Skip to content

VANSEN PHARMA INC.: 10-Q filed 2012-11-15

What VANSEN PHARMA INC. reported in its quarterly report filed 2012-11-15 (fiscal Q3 2012): 18 published measures, 55 facts as tagged in accession 0001477932-12-004456.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-15
Fiscal period
fiscal Q3 2012
Accession
0001477932-12-004456 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All VANSEN PHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-3018,092USD
At 2011-12-3118,766USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-30116,978USD
At 2011-12-31117,546USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-30-98,886USD
At 2011-12-31-98,780USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-3018,092USD
At 2011-12-3118,766USD
At 2010-12-3158USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-29,745USD274
2005-05-09 to 2012-09-30-242,667USD2702
2011-01-01 to 2011-09-30-17,092USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-25,674USD274
2005-05-09 to 2012-09-30-213,114USD2702
2011-01-01 to 2011-09-30-11,688USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-3025,000USD274
2005-05-09 to 2012-09-30233,058USD2702
2011-01-01 to 2011-09-3011,630USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-3018,092USD
At 2011-12-3118,766USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,764USD92
2012-01-01 to 2012-09-305,290USD274
2005-05-09 to 2012-09-3027,739USD2702
2011-07-01 to 2011-09-301,703USD92
2011-01-01 to 2011-09-305,086USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-30116,978USD
At 2011-12-31117,546USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-09-302,769USD
At 2011-12-313,988USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-303,525,000shares
At 2011-12-313,441,667shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-09-30-2,503USD
At 2011-12-31-1,852USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-9,631USD92
2012-01-01 to 2012-09-30-30,396USD274
2005-05-09 to 2012-09-30-245,170USD2702
2011-07-01 to 2011-09-30-4,650USD92
2011-01-01 to 2011-09-30-16,788USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-8,891USD92
2012-01-01 to 2012-09-30-29,745USD274
2005-05-09 to 2012-09-30-242,667USD2702
2011-07-01 to 2011-09-30-5,653USD92
2011-01-01 to 2011-09-30-17,092USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-303,627USD92
2012-01-01 to 2012-09-3010,955USD274
2005-05-09 to 2012-09-3056,375USD2702
2011-07-01 to 2011-09-301,649USD92
2011-01-01 to 2011-09-303,705USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,764USD92
2012-01-01 to 2012-09-30-5,290USD274
2005-05-09 to 2012-09-30-20,515USD2702
2011-07-01 to 2011-09-30-1,703USD92
2011-01-01 to 2011-09-30-5,086USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-3025,000USD274
2005-05-09 to 2012-09-30119,500USD2702

Inspect the source

Entity
VANSEN PHARMA INC. / CIK 0001378076
Captured
SEC response SHA-256
a4f0ed9133b6b7e9e5295515e2c8f107b3eff7e5edee25a65aab492b4189c5ca

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001378076.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))